Bio­gen col­lab­o­ra­tor Neu­roSense shares sec­ondary PhI­Ib da­ta for its ALS treat­ment

Neu­roSense an­nounced sec­ondary end­point da­ta for its ALS treat­ment, which is a com­bi­na­tion of the an­tibi­ot­ic ciprofloxacin and the NSAID cele­cox­ib.

In the Phase IIb …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER